Suggestions

Du même auteur

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

Archive ouverte | Cohen, Jonathon | CCSD

International audience

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Archive ouverte | Mato, Anthony, R | CCSD

International audience. Background: Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. We eva...

Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton’s Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study

Archive ouverte | Cohen, Jonathon, B | CCSD

Presentation during EHA2021 : E-Poster Presentation - Session title: Aggressive Non-Hodgkin lymphoma - Clinical. BackgroundDespite the marked efficacy of covalent BTK inhibitors (BTKi) in MCL, WM, and MZL, the devel...

Chargement des enrichissements...